Getting your patients started
No dose adjustments are required in patients with mild-to-moderate renal or hepatic impairment. NUEDEXTA has not been evaluated in patients with severe renal or hepatic impairment
Recommended dosage and administration
- Starting dose: One capsule daily by mouth for 7 days
- Maintenance dose: After 7 days, 1 capsule every 12 hours
Titrate from QD to Q12H on Day 81
1 capsule QD
1 capsule Q12H
Recommended maintenance dose
Instruct patients to not take more than 2 capsules in a 24-hour period and to make sure that there is an approximate 12-hour interval between doses
If a dose is missed, instruct patients to not take a double dose
The need for continued treatment should be reassessed periodically, as spontaneous improvement of PBA symptoms occurs in some patients
Document your diagnosis of PBA using
ICD-10 code F48.2a,2
- NUEDEXTA is categorized in the "Central Nervous System,
Other" pharmacologic class in the USP model formulary2,3
Script pad is for illustration purposes only and represents prescription for maintenance therapy after initial-week titration period with QD dosing.
aIntended for reference only. ICD-10-CM codes submitted to the payer must be determined by the provider/physician and accurately describe PBA as the diagnosis for which the patient receives NUEDEXTA treatment.
With the NUEDEXTA Savings Card,b most commercially insured patients may qualify to pay as little as $0† for a 90-day prescription of NUEDEXTA or $30 for a 30-day supply.
b Restrictions apply. Those eligible for any state or federally funded prescription programs, including Medicare, Medicaid, Medigap, VA, DOD, or TriCare, are not eligible for this program.
*Available to qualifying privately insured patients. Restrictions apply.
†Restrictions apply. Most commercially insured patients pay as little as $0 for a 90-day supply or $30 for a 30-day supply. Benefit cap applied regardless of copay amount.